Bertrand Arnulf

15.4k citations

167 papers · 4.8k indexed · 2 hit papers · h-index 37

Impact in

Hematology top 0.2%
- Multiple Myeloma Research and Treatments
Genetics top 1%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 77
- Multiple Myeloma Research and Treatments 66
Genetics 33
- Chronic Lymphocytic Leukemia Research 22

Co-authors: Olivier Hermine Jean‐Paul Fermand Philippe Moreau Bruno Royer Xavier Leleu Sebastian Grosicki Halyna Pylypenko Sylvie Chevret
Journals: Blood (35 papers)Journal of Clinical Oncology (13 papers)Leukemia (8 papers)British Journal of Haematology (6 papers)Haematologica (4 papers)
Partner nations: France United States Spain

In The Last Decade

Bertrand Arnulf

154 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

T cell malignancies after CAR T cell therapy in the DESCAR-T registry 2025 · 23 citations

Peers

Countries citing papers authored by Bertrand Arnulf

Since Specialization

Citations

This map shows the geographic impact of Bertrand Arnulf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Arnulf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Arnulf more than expected).

Fields of papers citing papers by Bertrand Arnulf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Arnulf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Arnulf. The network helps show where Bertrand Arnulf may publish in the future.

Co-authors

The 25 scholars most cited alongside Bertrand Arnulf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bertrand Arnulf Line = papers co-authored together Bertrand Arnulf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. Journal of Clinical Oncology ·Bertrand Arnulf, Tessa Kerre, Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, Helen Varsos, 森嘉信, Jordan M. Schecter, Kevin C. De Braganca, Yogesh Jethava, Qingxuan Song, Mythili Koneru, Muhammad Akram, Yaël C. Cohen, Wilfried Roeloffzen	2024	2
2	Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema Journal of the European Academy of Dermatology and Venereology ·文郎北目, María del Pilar Anto Rubio, T. Mahévas, Stéphanie Harel, Bruno Royer, Virginie Lemiale, Anne Brignier, Nathalie Parquet, M. Jachiet, Jean‐David Bouaziz, Francine Nicole Sicabalo, Bertrand Arnulf, Alexis Talbot	2024	2
3	Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma Cancer Immunology Research ·Limei Huang, Nina Orlova, E Juch, Antje Elger, Elisa Carlotta Kleinsorge de Kaczan, Caroline Choisy, C. Mironov, Qian Teng, David Garrick, Alexis Talbot, Jean‐Paul Fermand, Bertrand Arnulf, 大輔神田	2024	5
4	Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes Nephrology Dialysis Transplantation ·Adrien Joseph, Stéphanie Harel, Laurent Mesnard, Cédric Rafat, Sharanya Hemant, Alan D Pauw, Carole Philipponnet, Holly Edwards Voelp, Jean-Michel Rebibou, David Buob, Alexandre Hertig, Jacques Vargaftig, Jean‐Michel Halimi, Bertrand Arnulf, Abdullayeva Gulida O'rmonjon qizi, Bérangère S. Joly, Steven Grangé, Paul Coppo	2024	4
5	Monoclonal gammopathy of unknown significance in kidney transplanted patients: novel insights into long-term outcomes Nephrology Dialysis Transplantation ·Emmaline R. Sheahan, Daniel Isaacman, Juliette Gueguen, Gica Stefanescu Miralles, Gillian Divard, Olivier Aubert, Frank Bienaimé, Bertrand Arnulf, Dany Anglicheau, Frank Bridoux, Camille Cohen	2023	0
6	P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES HemaSphere ·Salomon Manier, Alexander M. Lesokhin, Mohamad Mohty, Rubén Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah M. Larson, Kaushikkumar D. Parmar, Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur Raje, Eric Leip, Sharon T. Sullivan, Mohamed Elmeliegy, Andrea Viqueira, Ajay K. Nooka	2023	3
7	The Sec61 translocon is a therapeutic vulnerability in multiple myeloma EMBO Molecular Medicine ·Ridwan, Caroline Choisy, Ludivine Baron, Véronique Mayau, Émeline Perthame, Ludovic Deriano, Bertrand Arnulf, Raphaël Borie, Gilles Dadaglio, Caroline Demangel	2022	17
8	CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment SHILAP Revista de lepidopterología ·Elisa Carlotta Kleinsorge de Kaczan, Limei Huang, Antje Elger, Caroline Choisy, C. Mironov, Stéphanie Harel, Bruno Royer, D Zhang, Alexis Talbot, David Garrick, Michèle Goodhardt, Geofrey Tremont, Mike F. Burbridge, Bertrand Arnulf, Raphaël Borie	2022	21
9	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma Transplantation and Cellular Therapy ·Hermann Einsele, Niels W.C.J. van de Donk, Bertrand Arnulf, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, William Deraedt, Hong Tian, Martin Vogel, Marlene J. Carrasco-Alfonso, Muhammad Akram, E. F. Whedon, Tonia Nesheiwat, María‐Victoria Mateos, Saad Z. Usmani	2021	0
10	Thiotepa intrathecal injections for myelomatous central nervous system involvement British Journal of Haematology ·Suzy R. Thomas, Alexis Talbot, Stéphanie Harel, Bruno Royer, Vanita, Anne–Marie Zagdanski, Isabelle Madelaine, Pierre Lemaire, Bertrand Arnulf	2021	6
11	Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signaling Leukemia ·Anne Ramos de Santana, Shu-Cheng ZHANG, Alexis Talbot, Caroline Choisy, Niswatul Mardiyah, Julien Lion, Wendy Cuccuini, Jean Soulier, Bertrand Arnulf, Raphaël Borie, Michèle Goodhardt, David Garrick	2021	2
12	Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma Hematological Oncology ·Cristiano Vieira Sobrinho, Alexis Talbot, Stéphanie Harel, Wendy Cuccuini, Laurence Gérard, Bertrand Arnulf	2020	2
13	The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling Leukemia ·Anne Ramos de Santana, Shu-Cheng ZHANG, Alexis Talbot, Caroline Choisy, Niswatul Mardiyah, Julien Lion, Wendy Cuccuini, Jean Soulier, Bertrand Arnulf, Raphaël Borie, Michèle Goodhardt, David Garrick	2020	36
14	Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016 Annales de Dermatologie et de Vénéréologie ·Charlotte Hurabielle, Maxime Battistella, C. Ram‐Wolff, C. Fite, Véronique Meignin, Jacqueline Rivet, Marie‐Dominique Vignon‐Pennamen, Edwin Crittenden, Emmanuel Raffoux, Bertrand Arnulf, Éric Oksenhendler, Flore Sicre de Fontbrune, Régis Peffault de Latour, Gèrard Socié, Jean‐David Bouaziz, Célèste Lebbé, Armand Bensussan, Martine Bagot	2018	11
15	Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 Blood ·Thierry Façon, Sagar Lonial, Brendan M. Weiss, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan M. Schecter, Amrita Krishnan	2017	15
16	Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study Blood ·Sagar Lonial, Jesús F. San Miguel, Joaquín Martínez‐López, María‐Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Ajai Chari, Luis Piñeiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan M. Schecter, Philippe Moreau	2017	9
17	Implication of the Long Non-Coding RNA Crnde in Multiple Myeloma Blood ·Anne Ramos de Santana, Niswatul Mardiyah, Alexis Talbot, Wendy Cuccuini, Jean‐Paul Fermand, Jean Soulier, Bertrand Arnulf, Jean Christophe Bories, Myung Gu Lee, David Garrick	2017	1
18	Le pomalidomide dans le myélome multiple La Revue de Médecine Interne ·Guillemette Fouquet, Margaret Macro, O. Decaux, Cécile Fohrer, Stéphanie Guidez, Hélène Demarquette, Lyudmila I. Provotorova, Chloé Prodhomme, Loïc Renaud, Claire Bories, Charles Herbaux, Lionel Karlin, Murielle Roussel, Lotfi Benboubker, Cyrille Hulin, Bertrand Arnulf, Xavier Leleu	2015	1
19	HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENALIDOMIDE TREATMENT (TX) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) Haematologica ·Kjetil TÃ ̧rseth, Dorothy Shipps, Alessandro Corso, Michel Delforge, Kevin Song, Meletios Α. Dimopoulos, 押田豊, C. Hulin, Philippe Rodon, Bertrand Arnulf, R. Foà, Albert Oriol, Shu Guo, J. Catalano, J. W. Jr.J. W. Richardson, Jason Van Oostendorp, Annette Ervin‐Haynes, Nesrin M. Handoka	2015	1
20	A Prospective Study of Bone Marrow Hematopoietic and Mesenchymal Stem Cells in Type 1 Gaucher Disease Patients PLoS ONE ·Séverine Lecourt, Enguerran Mouly, 曾捷, Audrey Cras, Raphaël Ceccaldi, X Liu, Christine Chomienne, Jean‐Pierre Marolleau, Bertrand Arnulf, Raphaël Porcher, Catherine Caillaud, Valérie Vanneaux, Nadia Belmatoug, Jérôme Larghero	2013	27

About Bertrand Arnulf

Bertrand Arnulf is a scholar working on Hematology, Genetics, Oncology, Nephrology and Immunology, having authored 167 papers that have together received 4.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (66 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (30 papers), Chronic Lymphocytic Leukemia Research (22 papers), CAR-T cell therapy research (15 papers), Protein Degradation and Inhibitors (15 papers), Peptidase Inhibition and Analysis (13 papers), T-cell and Retrovirus Studies (12 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (763 citations), Oncology (1.6k citations), Nephrology (351 citations) and Immunology (1.0k citations). Bertrand Arnulf has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Olivier Hermine, Jean‐Paul Fermand, Philippe Moreau, Bruno Royer, Xavier Leleu, Sebastian Grosicki, Halyna Pylypenko, Sylvie Chevret, Helgi van de Velde and William Deraedt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact